iX Biopharma Ltd. announced that on Jan, 9 2026 it allotted and issued 51,155 new ordinary shares following the exercise of warrants at an exercise price of 0.06 Singapore dollars per share.
The issuance lifts the company’s total share base to 958,101,805 from 958,050,650.
The newly issued shares rank pari passu with the existing shares and are expected to begin trading on the Singapore Exchange on or around Jan, 13 2026.
To date, 3,142,360 warrants, equivalent to 5.46% of all warrants previously issued, have been exercised. The remaining 54,367,119 warrants, each exercisable at 0.06 Singapore dollars, will expire on Jul, 18 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.